Although early studies showed that only the rare D816V-negative cases were sensitive to imatinib, new TKIs have shown inhibitory activity also against MCs carrying the D816V KIT mutation, which has expanded the current therapeutic landscape in SM. The gene discussed is KIT; the disease is systemic mastocytosis.